All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL hub

ALL hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site aml-hub.com.
2022-06-06T14:53:26.000Z

EHA2022 abstracts: What's hot in MDS?

By Becky Gribbell, Ella Dixon
Jun 6, 2022
Share:

Bookmark this article

To help navigate the exciting content being presented at the EHA2022 Congress, the MDS Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MDS.

Top abstracts

P496

Clinical characteristics of secondary myeloid neoplasms in patients with inflammatory bowel disease

P508

Real life experience using front-line CPX-351 for therapy-related and AML-MRC: Results from the Spanish PETHEMA registry

P735

The role of SF3B1 mutations in myelodysplastic syndromes

P741

DDX41 mutations define a unique subtype of myeloid neoplasms

P752

Targeting S100A9 in the myelodysplastic inflammatory bone marrow microenvironment by tasquinimod improves the supportive function of mesenchymal stromal cells

P754

Initial results of phase I/II study of azacitidine in combination with quizartinib for patients with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutation

P757

Results of a phase 1 study of azacitidine combined with venetoclax for treatment-naive and relapsed high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

P763

Venetoclax with azacitidine in relapse/refractory higher risk myelodysplastic syndrome: updated phase 1 results

P778

Long-term utilization and benefit of luspatercept in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial

P780

Combination therapy of eltrombopag and cyclosporine A can improve hematopoiesis in patients with lower risk myelodysplastic syndrome

P784

A phase I/II study of venetoclax in combination with ASTX727 (decitabine/cedazuridine) in treatment‐naïve high‐risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)

P785

Current cardiovascular disease risk prediction models are not applicable in MDS patients: preliminary results of a prospective observational single-centre cohort study

PB1926

Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among US patients with lower-risk myelodysplastic syndromes (LR-MDS)

S160

Molecular determinants of disease progression after hypomethylating agent therapy in Ras pathway mutant chronic myelomonocytic leukemia at the single-cell level

S165

Integrated genetic diagnostics of patients with early onset of de novo myelodysplastic syndromes

S166

Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results

S167

Prediction of relapse after allogeneic stem cell transplantation using individualized measurable residual disease markers; the prospective Nordic study NMDSG14B

S168

Erythropoietin stimulation agents significantly improves outcome in lower risk MDS

S169

Clinical and molecular markers for predicting response to romiplostim treatment in lower-risk myelodysplastic syndromes

EHA2022 abstracts

To download this document, click below.

Download here

More about...
EHAEHA 2022

Related articles

Add bookmark

How do we differentiate high-risk MDS from AML?

During the EHA 2022 Congress, the MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, How do we differentiate high-risk MDS from AML?

Aug 9, 2022
Add bookmark

How do we differentiate high-risk MDS from AML?

During the EHA 2022 Congress, the MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, How do we differentiate high-risk...

Aug 9, 2022
Add bookmark

How could venetoclax combinations improve outcome in high-risk MDS?

During the EHA 2022 Congress, the MDS Hub was pleased to speak with Jacqueline Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How could venetoclax combinations improve...

Jul 15, 2022
Add bookmark

How could venetoclax combinations improve outcome in high-risk MDS?

During the EHA 2022 Congress, the MDS Hub was pleased to speak with Jacqueline Garcia, Dana-Farber Cancer Institute, Boston, US. We...

Jul 15, 2022

Newsletter

Subscribe to get the best content related to MDS delivered to your inbox